Evidence map›Paper›PMID 35966577›Full record

ArticleTheranostics2022

Engineered extracellular vesicles with high collagen-binding affinity present superior

Dake Hao, Lu Lu, Hengyue Song, Yixin Duan, Jianing Chen, Randy Carney, Jian Jian Li, Ping Zhou, Jan Nolta, Kit S Lam and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Dake HaoDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Lu LuDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Hengyue SongDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Yixin DuanDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA.
Jianing ChenDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Randy CarneyDepartment of Biomedical Engineering, University of California Davis, Davis, CA 95616, USA.
Jian Jian LiDepartment of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA.
Ping ZhouStem Cell Program, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Jan NoltaStem Cell Program, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
J Kent LeachDepartment of Orthopaedic Surgery, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Diana L FarmerDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Alyssa PanitchDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
Aijun WangDepartment of Surgery, University of California Davis, Sacramento, CA 95817, USA.
University of California, Davis · USShriners Hospitals for Children - Northern California · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida TherapyR01NS115860 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARMER, DIANA LEE, WANG, AIJUN · 2020 to 2024
$2.5M
Fetal Tissue Engineering to Treat Spina Bifida Before BirthR01NS100761 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WANG, AIJUN · 2017 to 2021
$1.7M
NCI NIH HHS P30 CA093373NINDS NIH HHS R01 NS100761NINDS NIH HHS R01 NS115860
6 · The paper itself

Abstract

Although stem cell-derived extracellular vesicles (EVs) have remarkable therapeutic potential for various diseases, the therapeutic efficacy of EVs is limited due to their degradation and rapid diffusion after administration, hindering their translational applications. Here, we developed a new generation of collagen-binding EVs, by chemically conjugating a collagen-binding peptide SILY to EVs (SILY-EVs), which were designed to bind to collagen in the extracellular matrix (ECM) and form an EV-ECM complex to improve EVs'

Indexed as

Extracellular VesiclesMesenchymal Stem CellsAnimalsDisease Models, AnimalIschemiaMiceStem CellsWound Healingcollagen-bindingExtracellular vesiclein situ retentiontherapeutic efficacytissue repair

Identifiers

PMID35966577
PMCPMC9373818
OpenAlexW4291130999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.